You are subscribed to the Formulary News Capsule. Unsubscribe here.

Formulary

Print Subscribe

Digital Edition Subscribe

November 9, 2012

Web Version  |  Digital Edition  |  Share with a colleague

Facebook Like   Twitter Tweet

Today's Headlines

Antiplatelet guidelines updated

The Society of Thoracic Surgeons has updated its clinical practice guidelines on use of antiplatelet drugs during heart surgery. The new guideline, published in the November 2012 issue of The Annals of Thoracic Surgery, takes into account newly available antiplatelet therapies, new scientific information, and a broader use of antiplatelet drugs such as before lung and vascular procedures, according to Newswise. » Full article

Election analysis: Washington's power

With President Obama's re-election, implementation of the Affordable Care Act will move forward, full speed ahead, according to one industry expert » Full article

FDA expands rivaroxaban use

FDA has expanded the approved use of oral anticoagulant rivaroxaban (Xarelto, Janssen) to include 3 new indications: treatment of deep vein thrombosis (DVT), treatment of pulmonary embolism (PE), and reducing the risk of recurrent DVT and PE following initial treatment. » Full article

FDA approves tofacitinib for RA

FDA has approved tofacitinib (Xeljanz, Pfizer) to treat adults with moderately to severely active rheumatoid arthritis who have had an inadequate response to, or who are intolerant of, methotrexate.
» Full article

CONTINUING EDUCATION

New CPE Series: November activity available now

Welcome to the third activity of our CPE series: Medication Therapy Management (MTM) in Patients with Diabetes, which has been designed for pharmacists who take care of patients with diabetes. You can earn up to 14 credits from September 2012-March 2013 with 7 monthly knowledge-based activities. The November activity will cover oral antidiabetes agents and noninsulin injectables for diabetes care.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to login.

Coming soon - All users will be required to provide their NABP e-Profile ID when logging into the Drug Topics' FREE CPE. This new process requires all pharmacists and pharmacy technicians to provide their NABP e-Profile ID prior to accessing the system. If you have not done so, you can obtain your NABP e-Profile ID now at www.MyCPEmonitor.net This profile will enable you to have one login for all the NABP programs and services you will need throughout your career.

ADVERTISEMENT

PAC Delivers More Predictable GER than AWP - click here to see example

New drug price type, Predictive Acquisition Cost (PAC), delivers more predictable and stable generic effective rate (GER) than Average Wholesale Price (AWP). Click here to see a scenario illustrating how PAC compares to AWP for GER variability across drug groups.See example now.

EDITOR'S PICK

Modifying antiplatelet therapy based on platelet function testing does not improve outcomes in stroke/TIA patients

In the quest to adopt personalized medicine approaches, optimizing antiplatelet therapy based on platelet function testing is controversial. But data from a team led by a researcher at the Cleveland Clinic failed to demonstrate improved outcomes following intensification of antiplatelet therapy on the basis of platelet function testing in patients with stroke or transient ischemic attack (TIA). » Full article

Survey

Copay discount coupon/cards being offered by brand-name drug companies have the potential to counter the cost-efficiency goals of a tiered drug benefit design. What do you see as the most practical, yet effective strategy payors/PBMs can implement to offset this activity?


a) Further broaden the gap between copay dollar value between preferred and non-preferred brand drug tiers.

b) Demand increase formulary rebates requested from manufacturers of preferred products.

c) Implement more aggressive utilization management (PA, Step, Therapeutic Interchange, etc.) to specifically target these products.

d) Enhanced employment of a closed-formulary benefit design.

e) No action, as I dont believe this couponing will have significant effects.


Respond here and see what your colleagues think too.Want to see the results of our last survey. Click here.

 

Subscribe Now!

You must click here to continue receiving the Formulary News Capsule

Related Articles

Triple-antiplatelet therapy

Health reform

Rivaroxaban and PE

Focus on: Tofacitinib

RESOURCES

Drug Watch

Latest Clinical News

What can Formulary do for you?

Take our super short survey TODAY! http://www.surveygizmo.com/s3/1050662/Formulary-Readers

 
Powered by Modern Medicine Advanstar Medical Communications Group